Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.5K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.5K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

465
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
465
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

656
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
656
Angina IV: Management01:26

Angina IV: Management

330
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
330
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

385
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
385
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

741
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
741

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gene Silencing of ANGPTL3 Induces PCSK9: Exploring the Biological Significance in the Hepatoma Huh7 Cell Line.

Cells·2026
Same author

Association between atrial fibrillation and systemic inflammation with muscle mass and strength trajectories in old age.

GeroScience·2026
Same author

Sex and gender differences in technology-based rehabilitation for people with stroke: A scoping review.

Clinical rehabilitation·2026
Same author

Comparing the 2025 ESC/EAS Focused Update and the 2026 ACC/AHA Dyslipidemia Guideline: Convergences, Divergences, and Practical Implications.

Cardiovascular drugs and therapy·2026
Same author

Integrating CYP2D6 and MATE1 activities in drug-drug interaction assessment: Insights from newly developed antidepressant drug ammoxetine.

The Journal of pharmacology and experimental therapeutics·2026
Same author

High-frequency pseudo-hypofunction of the superior semicircular canal dehiscence syndrome: a vHIT - oVEMP dissociation explained by hydrodynamic energy loss.

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery·2026

Related Experiment Video

Updated: Feb 20, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.1K

The 2025 ESC/EAS Dyslipidaemia Focused Update: Clinical Interpretation and Practical Implications.

Luca Bonanni1,2, Ada Cutolo3,4, Nicola Ferri5

  • 1Department of Medicine, Ospedale dell'Angelo, Venice, Italy. luca.bonanni@aulss3.veneto.it.

Cardiovascular Drugs and Therapy
|February 18, 2026
PubMed
Summary

The 2025 ESC/EAS Dyslipidaemia Focused Update refines lipid-lowering strategies, emphasizing faster treatment intensification and new therapies for cardiovascular risk reduction. It promotes personalized, sustained low-density lipoprotein cholesterol (LDL-C) management for better outcomes.

Keywords:
Cardiovascular preventionDyslipidaemia ManagementLDL Cholesterol TargetsESC/EAS GuidelinesGuideline UpdateLipid-Lowering Therapy

More Related Videos

Assessing Whole-Body Lipid-Handling Capacity in Mice
07:57

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

4.8K
Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

12.5K

Related Experiment Videos

Last Updated: Feb 20, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.1K
Assessing Whole-Body Lipid-Handling Capacity in Mice
07:57

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

4.8K
Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

12.5K

Area of Science:

  • Cardiology
  • Lipidology
  • Preventive Medicine

Background:

  • The 2019 European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) guidelines provide a framework for dyslipidaemia management.
  • Emerging evidence necessitates a focused update to incorporate new findings and refine clinical practice.

Purpose of the Study:

  • To revise and update the 2019 ESC/EAS Dyslipidaemia guidelines with recent evidence.
  • To provide actionable recommendations for optimizing lipid-lowering therapies before the next comprehensive guideline revision.

Main Methods:

  • Integration of new clinical trial data and real-world evidence.
  • Re-evaluation of risk stratification tools, including SCORE2/SCORE2-OP, lipoprotein(a) [Lp(a)], and coronary artery calcium (CAC) scoring.
  • Assessment of novel lipid-lowering agents and treatment intensification strategies.

Main Results:

  • Low-density lipoprotein cholesterol (LDL-C) treatment targets remain consistent.
  • Emphasis on accelerated therapeutic intensification and expanded use of combination therapies.
  • Introduction of new evidence supporting bempedoic acid, inclisiran, and evinacumab for specific patient groups.
  • Reinforcement of proactive, early-intensification strategies in acute coronary syndrome (ACS) settings.

Conclusions:

  • The update enhances the operational framework for LDL-C management.
  • Promotes earlier, personalized, and sustained lipid lowering to minimize cumulative atherosclerotic exposure.
  • Offers refined guidance for managing dyslipidaemia, particularly in high-risk individuals and those with statin intolerance.